A role for triterpenes in the cancer setting is gradually emerging. Bringing together the efforts of both academy and industry, this book highlights the most significant research results achieved with pentacyclic triterpenic compounds, providing clues for lead compound selection and targets to be exploited. It will work as an extension of the continuous discussion concerning the introduction of these agents into the clinical setting for chemotherapy and chemoprevention purposes.